Text Size:AAA

人 VEGFR3 / FLT-4 ELISA Kit

  • Human VEGFR3 / FLT-4 ELISA Kit, TYPICAL DATA
  • Human VEGFR3 / FLT-4 ELISA Kit, SPECIFICITY
产品数据评论相关产品
检测原理
Solid Phase Sandwich ELISA
预期用途
For the quantitative determination of Human VEGFR3 / FLT-4 concentration in serum.
The use of this kit for other sample types need be validated by the end user due to the complexity of natural targets and unpredictable interference.
线性范围
46.88-3000 pg/mL
灵敏度
The minimum detectable dose of Human VEGFR3 / FLT-4 is typically less than 7.95 pg/mL. The MDD was determined by adding three standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration.
试剂盒组分
1. 96 well microplate coated with Capture Antibody
2. Detection Antibody conjugated to HRP
3. Standards
4. Wash Buffer Concentrate
5. Dilution Buffer Concentrate
6. Color Reagent A
7. Color Reagent B
8. Stop Solution
储存方法
Unopened Kit: Store at 2 - 8℃
Opened/Reconstituted Reagents: Please refer to CoA
 FLT4 ELISA 检测试剂盒标准曲线
Human VEGFR3 / FLT-4 ELISA Kit, TYPICAL DATA
[点击查看大图]
Caption:
This standard curve is only for demonstration purposes. A standard curve should be generated for each assay.
 FLT4 ELISA 检测试剂盒特异性
Human VEGFR3 / FLT-4 ELISA Kit, SPECIFICITY
[点击查看大图]
Caption:
This assay recognizes both recombinant and natural Human VEGFR3. The factors listed above were prepared at 50 ng/mL in dilution buffer and assayed for cross-reactivity. No cross-reactivity was observed.
Recombinant human VEGFC does not cross-react in this assay but does interfere at concentrations greater than 0.5 ng/mL.

VEGFR3/FLT-4  研究背景

Vascular endothelial growth factor receptor 3 (VEGFR3), also known as FLT-4, together with the other two members VEGFR1 (FLT-1) and VEGFR2 (KDR/Flk-1) are receptors for vascular endothelial growth factors (VEGF) and belong to the class III subfamily of receptor tyrosine kinases (RTKs). The VEGFR3 protein is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Mutations in VEGFR3 have been identified in patients with primary lymphoedema. The VEGF-C/VEGF-D/VEGFR3 signaling pathway may provide a target for antilymphangiogenic therapy in prostate cancer, breast cancer, gastric cancer, lung cancer, non-small cell lung cancer (NSCLC), and so on.

Immune Checkpoint   Immunotherapy   Cancer Immunotherapy   Targeted Therapy

 VEGFR3/FLT-4  参考资料
  • Shushanov S, et al. (2000)VEGFc and VEGFR3 expression in human thyroid pathologies. Int J Cancer.86(1): 47-52.
  • Iljin K, et al. (2001) VEGFR3 gene structure, regulatory region, and sequence polymorphisms. FASEB J. 15(6): 1028-36.
  • Liu XE, et al. (2004) Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J Gastroenterol. 10(3): 352-5.
  • Stearns ME, et al. (2004) Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab Invest. 84(6): 785-95.
  • Size / Price
    货号: KIT10806-1
    目录价: 
    单价:      (You Save: )

    Datasheet & Documentation

    产品数据可能随批次变化,最新数据请详见随货说明书。
    请注意:所有产品都是“仅用于科研,而不能用于诊断或治疗用途”